Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CD19/CD20 Dual-Target in vivo CAR-T Lentiviral

Gene therapy (Lentiviral vector) · Acts on B-lymphocyte antigen CD19 (CD19) and B-lymphocyte antigen CD20 (MS4A1)

Phase 1 Most advanced trial
2 Registered trials

What is CD19/CD20 Dual-Target in vivo CAR-T Lentiviral?

CD19/CD20 Dual-Target in vivo CAR-T Lentiviral is a lentiviral product intended to make CAR-T cells inside the body, directed at the CD19 and CD20 antigens on B cells. It is being studied in relapsed or refractory B-cell malignancies, with bridging therapy given before infusion if needed.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy (Lentiviral vector)
Targets
B-lymphocyte antigen CD19 (CD19) (antigen), B-lymphocyte antigen CD20 (MS4A1) (antigen)
Mechanism
Acts on B-lymphocyte antigen CD19 (CD19) and B-lymphocyte antigen CD20 (MS4A1)
Therapy area
Oncology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07763938 Phase 1 Relapsed/Refractory B-cell Malignancies Not yet recruiting LEGN
NCT07002112 Phase 1 Relapsed/Refractory B-cell Malignancies Recruiting LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Relapsed/Refractory B-cell Malignancies

Other drugs acting on CD19 / MS4A1

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.